Ossium Health

10/29/2026

Ossium CEO Kevin Caldwell on the Nasdaq tower in Times Square, recognized as a 2026 Biocom Catalyst Award winner.

10/24/2026

In a new Clinical Leader interview with Abby Proch, our CEO Kevin Caldwell explains why Ossium took a multi-center approach from its earliest study.

To date, 29 patients have been treated with Ossium’s organ donor-derived bone marrow at roughly half as many centers, each using the conditioning regimens and post-transplant care its team already knew. The goal was to generate data that reflects real-world transplant practice.

We're now carrying that approach into PRESERVE II, a 300-patient, three-arm study that begins enrollment in 2027.

Read the full interview:

Ossium CEO Kevin Caldwell explains how an unconventional multisite Phase 1 trial is shaping the companys novel bone marrow product’s path ahead.

10/14/2026

This week, AABB selected Ossium’s abstract, "On-demand, High-quality Hematopoietic Stem Cells from Deceased Organ Donors," as a Top Poster at the 2026 Annual Meeting. The findings show stem cell viability preserved through cryopreservation and 100% engraftment in evaluable transplant recipients.

Attending ? Join the Ossium team on the Curated Top Posters Tour: Innovations in Cellular Therapies, Sunday, Oct. 18, 12:15–1 p.m. ET, Biotherapies Pavilion.

Read the full release:

Ossium Health’s on-demand organ donor bone marrow data selected as a Top Poster at the 2026 AABB Annual Meeting...

09/25/2026

As the Journey of Hope 2026 comes to an end, it doesn't feel like an ending at all. In many ways, it feels like a beginning.

Over the past week, we've seen incredible support from around the world, with communities coming together and thousands of new blood stem cell donors joining the global effort to give patients hope.

Let's keep that momentum going. Keep following, sharing, and raising awareness, because every week more than 22,000 people hear the words, "You have blood cancer." At the same time, our global community helps more than 2,600 patients each week receive a second chance at life through a stem cell transplant.

But there is still a gap to close. With your support, we can help ensure that more patients find their match and get the transplant they need.

A heartfelt thank you to all our partners for supporting World Marrow Donor Day, standing alongside the WMDA community, raising awareness worldwide, and providing WMDD grants that help reduce inequality in access to transplantation. Thank you DKMS Group, Sanofi, NMDP, Gift of Life Marrow Registry, Appfire, Ossium Health and NecstGen.

Together, we are creating more second chances, more hope, and more lives saved.

09/01/2026

Last week we welcomed Congresswoman Erin Houchin, who represents Indiana's 9th District and serves on the House Energy and Commerce Committee, to our Indianapolis facility.

Rep. Houchin toured our lab and met the team processing and banking bone marrow from deceased organ donors, and learned about how the process works end to end — from recovery through cryopreservation to a patient's bedside.

We're grateful for her time and her interest in the patients this work is for.

07/28/2026

We're honored to be named to the Forbes Next Billion-Dollar Startups list, Forbes' annual selection of 20 fast-growing U.S. companies it considers most likely to reach a $1 billion valuation.

Ten years ago, co-founders Kevin Caldwell and Erik Woods set out to prove that bone marrow from organ donors could be recovered, cryopreserved, and made available to patients on demand. Today, 28 patients have received transplants with bone marrow from Ossium’s bank.

This recognition belongs to our team, our clinical partners, and the donor families whose gift makes every one of these transplants possible.

The Forbes Next Billion-Dollar Startups 2026 list highlights venture-backed companies likely to become unicorns. Learn more about these fast-growing startups.

06/18/2026

06/17/2026

When time was running out for 14-year-old Noah Britt, speed made all the difference. He's now the first pediatric patient to be treated with a bone marrow transplant using organ donor stem cells from Ossium's bank.

After a courageous fight with acute myeloid leukemia, Noah's initial living donor bone marrow transplant failed. With his condition worsening and time running short, his care team at Riley Children's Health needed another donor, fast. They identified a suitable donor in Ossium's bank, where stem cell units are available on demand. Because the cells were ready when Noah needed them, his physicians were able to move forward in days rather than months, a critical difference that gave him another chance at life.

At Ossium, we measure success in lives saved. Stories like Noah's are exactly why we built this bank, and why we keep working to expand access for the patients who need it most.

🔗

Leukemia patient is the first child in the world to successfully undergo a stem cell transplant using cells from a deceased donor.

05/28/2026

When longevity medicine arrives at scale, it will depend as much on logistics as on biology. That's the throughline of a new Longevity.Technology feature on Ossium and a conversation with our Co-Founder & CEO Kevin Caldwell.

Bone marrow transplantation has been quietly extraordinary for decades: a procedure that rebuilds a patient's entire blood and immune system from donor-derived stem cells. But it has remained dependent on living donors, narrow collection windows, and choreography that often breaks when disease moves faster than the donor coordination.

Ossium is building the alternative: a cryopreserved bank of organ donor-derived bone marrow, processed and characterized for on-demand use.

The near-term goal is access. The longer-term implication, as the piece explores, is harder to ignore: if hematopoietic stem cells sit at the root of immune decline, the infrastructure for transplantation may also be infrastructure for immune renewal.

🔗

As immunosenescence drives systemic disease, banked bone marrow could scale from a transplant tool into healthspan infrastructure.

05/26/2026

Ossium Health CEO Kevin Caldwell recently joined Chris Leidli on for a conversation about how we're reshaping the future of bone marrow transplantation and immune health.

The episode covers:
🔹 Why bone marrow transplants – one of the most powerful procedures in medicine — have been historically underutilized
🔹 How Ossium’s supply of banked bone marrow has reduced transplant lead times from months to as little as 48 hours
🔹 The potential for our bone marrow bank to serve as a foundation for a new generation of allogeneic, off-the-shelf cell therapies
🔹 How bone marrow transplants could eventually be used proactively to reset an aging immune system before catastrophic disease strikes

🎧 Listen here:

Podcast Episode · Rx for Biotech · April 28 · 29m